Difluprednate improves results

Article

Pre- and postoperative treatment with the potent corticosteroid difluprednate ophthalmic emulsion 0.05% signficantly improves outcomes after cataract surgery compared with use of prednisolone acetate ophthalmic suspension 1% and so results in improved patient satisfaction, according to one expert.

The second eye was operated on after a 2-week interval, and all surgeries were uncomplicated. The corticosteroids were administered in a pulsed regimen perioperatively (10 doses) and then with a 2-week tapering course postoperatively.

"Despite advances in cataract surgery technique and technology, we have been disappointed that many patients still have cloudy corneas or even mild corneal thickening postoperatively that decreases their quality of vision," said Dr. Donnenfeld, founding partner, Ophthalmic Consultants of Long Island and Connecticut, and clinical professor of ophthalmology, New York University, New York. "Results of our controlled study document that use of difluprednate addresses this issue and improves the postoperative results in statistically and clinically significant ways.

"I have been using difluprednate in all of my cataract surgery patients for [more than] a year," he added. "My patients are much happier because of the 'wow' effect on their vision and are more likely to spread the word to everyone they know about their positive experience."

Several lines of evidence led Dr. Donnenfeld and colleagues to consider the pulsed difluprednate regimen as a solution to achieving improved outcomes after cataract surgery. Recognizing that high-dose corticosteroids are used in neurology and neurosurgery to reduce post-traumatic neuronal degeneration, improve neuronal function, and prevent neuronal cell death after spinal cord injury, they reasoned that because the corneal endothelium is also of neuroectodermal origin, a similar regimen might be beneficial for corneal protection in cataract surgery.

"I have found difluprednate to be the steroid of choice for all complicated cataract [procedures]," said Dr. Holland, director of cornea services, Cincinnati Eye Institute, and professor of ophthalmology, University of Cincinnati. "These include cases involving iris manipulation with hooks or rings, prolonged phaco time due to a dense cataract, capsule fixation or IOL suturing, and capsule tear or vitreous loss."

Recent Videos
EnVision Summit Cochair Cecelia Koetting, OD, FAAO, Dipl ABO, says that attendees should get ready for more discussion-based panels at this year's conference.
From contact lens dropout to addressing diabetic retinopathy in rural communities, optometrists choose an area of eye care research that they would expand, given the appropriate resources.
Bonnie An Henderson in an interview for the EnVision Summit
From new treatments on the horizon for macular degeneration to strengthening comanagement ties, optometrists cite a lot to be excited about in the coming year.
EnVision Summit cofounder and program chair Dr Bonnie Henderson chats about collaborative eye care
Practice owners testify to the importance of trying new things, not being afraid to fail, and utilizing community as a resource when starting up a new practice.
Bonnie An Henderson in an interview for the EnVision Summit
Optometrists reflect on their residency experiences and provide advice to current residents.
EnVision Summit Co-chairs Sherrol Reynolds, OD, FAAO; Katie Rachon, OD, FAAO, Dipl ABO; Jessica Steen, OD, FAAO, Dipl ABO; and Cecelia Koetting, OD, FAAO, Dipl ABO; express excitement for the upcoming conference and why optometrists should attend.
© 2025 MJH Life Sciences

All rights reserved.